Drug Profile
Lazertinib - Janssen Biotech/Yuhan
Alternative Names: C-18112003-G; GNS 1480; JNJ 73841937; JNJ-1937; JNJ-73841937-AAA; Lazertinib mesylate monohydrate; Leclaza; YH-25448Latest Information Update: 25 Jan 2024
Price :
$50
*
At a glance
- Originator Oscotec
- Developer Janssen Biotech; Janssen Research & Development; Yuhan
- Class Amides; Aniline compounds; Antineoplastics; Dimethylamines; Ethers; Morpholines; Pyrimidines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer
Most Recent Events
- 31 Dec 2023 Preregistration for Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in European Union (PO) in Q4 2023
- 22 Dec 2023 Preregistration for Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA (PO)
- 20 Nov 2023 Preregistration for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)